Advertisement
Singapore markets closed

  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     

  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • Bitcoin USD

    63,637.57
    +1,873.52 (+3.03%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • Dow

    38,675.68
    +450.02 (+1.18%)
     

  • Nasdaq

    16,156.33
    +315.37 (+1.99%)
     

  • Gold

    2,310.10
    +0.50 (+0.02%)
     

  • Crude Oil

    77.99
    -0.96 (-1.22%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     

  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     

  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Bayer exploring sale of dermatology business - Bloomberg

Reuters

(Reuters) - German chemicals and crop pesticides firm Bayer AG is exploring the sale of its dermatology business to push forward its deal with Monsanto Co, Bloomberg reported, citing sources.

Bayer is working with JPMorgan Chase & Co on the sale, which could fetch more than 1 billion euros ($1.12 billion), the report said.

Bayer said on Monday it was willing to offer more than $65 billion, a 2 percent increase on its previous offer for the world's largest seeds company Monsanto.

The dermatology business could attract interest from existing makers of skincare products including Nestle SA's Galderma, Allergan Plc and Almirall SA, as well as private equity firms, according to the Bloomberg report.

Bayer and J.P. Morgan were not immediately available for comment.

(Reporting by Aishwarya Venugopal in Bengaluru; Editing by Shounak Dasgupta)